BeOne Medicines' sonrotoclax gets FDA breakthrough therapy status
Source: SeekingAlpha
2025-10-13 09:08:36 ET
More on BeiGene
- BeOne Medicines AG (ONC) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
- BeOne Medicines: Brukinsa's Leadership And Royalty Sale Signal A Stronger Future
- BeOne Medicines Ltd. 2025 Q2 - Results - Earnings Call Presentation
- Trump’s 100% drug tariffs send pharma stocks lower
- BeOne Medicines succeeds in Phase 1/2 study for lymphoma therapy
Read the full article on Seeking Alpha
For further details see:
BeOne Medicines' sonrotoclax gets FDA breakthrough therapy status
BeiGene
NASDAQ: BEIGF
BEIGF Trading
0.0% G/L:
$23.75 Last:
100 Volume:
$23.75 Open:
BEIGF Latest News
BEIGF Stock Data
$38,603,023,416
747,457,849
N/A
299
N/A
Biotechnology & Life Sciences
Healthcare
CH
Basel
